ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ARDX Ardelyx Inc

7.29
-0.12 (-1.62%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 6,719,062
Bid Price 7.26
Ask Price 7.30
News (1)
Day High 7.585

Low
3.16

52 Week Range

High
10.13

Day Low 7.245
Company Name Stock Ticker Symbol Market Type
Ardelyx Inc ARDX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.12 -1.62% 7.29 19:59:25
Open Price Low Price High Price Close Price Prev Close
7.41 7.245 7.585 7.30 7.41
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
22,691 6,719,062 $ 7.42 $ 49,862,314 - 3.16 - 10.13
Last Trade Time Type Quantity Stock Price Currency
19:58:04 5 $ 7.2896 USD

Ardelyx (ARDX) Options Flow Summary

Overall Flow

Bearish

Net Premium

-7k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Ardelyx Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.69B 232.69M - 124.46M -66.07M -0.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ardelyx News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ARDX Message Board. Create One! See More Posts on ARDX Message Board See More Message Board Posts

Historical ARDX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week7.868.027.2457.624,153,124-0.57-7.25%
1 Month9.679.837.2458.445,559,536-2.38-24.61%
3 Months6.14510.135.948.706,354,5681.1518.63%
6 Months4.1510.133.166.426,417,8743.1475.66%
1 Year4.3110.133.165.345,877,3232.9869.14%
3 Years6.3310.130.49023.006,752,3910.9615.17%
5 Years2.8510.43430.49023.214,309,5684.44155.79%

Ardelyx Description

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Your Recent History

Delayed Upgrade Clock